Autor: "Koerber SA" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Autorzy:: Solomonidou N; Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.
Germanou D; Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.
Strouthos I; Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.
Karagiannis E; Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.
Farolfi A; Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.
Peeken JC; Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.; Department of Radiation Sciences (DRS), Institute of Radiation Medicine (IRM), Helmholtz Zentrum, Munich, Germany.; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany.
Vogel ME; Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.; Department of Radiation Sciences (DRS), Institute of Radiation Medicine (IRM), Helmholtz Zentrum, Munich, Germany.; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany.
Vrachimis A; Department of Nuclear Medicine, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.; C.A.R.I.C. Cancer Research & Innovation Center, Limassol, Cyprus.
Spohn SKB; Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg im Breisgau, Germany.; Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
Shelan M; Department of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.
Aebersold D; Department of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.
Grosu AL; Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg im Breisgau, Germany.
Ceci F; Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Kroeze SGC; Northern Sydney Cancer Centre, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia.
Guckenberger M; Northern Sydney Cancer Centre, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia.
Fanti S; Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Belka C; Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Hruby G; Northern Sydney Cancer Centre, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia.
Scharl S; Department of Radiation Oncology, University of Ulm, Ulm, Germany.
Wiegel T; Department of Radiation Oncology, University of Ulm, Ulm, Germany.
Bartenstein P; Department of Nuclear MedicineUniversity Hospital, LMU Munich, Munich, Germany.
Henkenberens C; Department of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany.
Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Schmidt-Hegemann NS; Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Ferentinos K; Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.
Zamboglou C; Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany. .; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg im Breisgau, Germany. .; Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany. .; German Oncology Center, University Hospital of the European University Cyprus, Limassol, Cyprus. .; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Jul; Vol. 50 (8), pp. 2529-2536. Date of Electronic Publication: 2023 Mar 11.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/radiotherapy
Prostatic Neoplasms*/surgery
Male ; Humans ; Prostate-Specific Antigen ; Positron Emission Tomography Computed Tomography/methods ; Gallium Radioisotopes ; Retrospective Studies ; Androgen Antagonists ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Recurrence, Local/radiotherapy ; Salvage Therapy ; Prostatectomy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).
Autorzy:: Regnery S; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ristau J; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Weykamp F; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hoegen P; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sprengel SD; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Paul KM; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Buchele C; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Klüter S; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Rippke C; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Renkamp CK; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Pohl M; Institute of Medical Biometry, University Hospital Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.
Meis J; Institute of Medical Biometry, University Hospital Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.
Welzel T; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Adeberg S; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hörner-Rieber J; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. .; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. .; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), Heidelberg, Germany. .; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. .; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2022 May 25; Vol. 17 (1), pp. 102. Date of Electronic Publication: 2022 May 25.
Typ publikacji:: Clinical Trial, Phase I; Journal Article
MeSH Terms:: Lung Neoplasms*/pathology
Lung Neoplasms*/radiotherapy
Lung Neoplasms*/surgery
Radiosurgery*/methods
Radiotherapy, Image-Guided*/methods
Humans ; Magnetic Resonance Spectroscopy ; Prospective Studies ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial.
Autorzy:: Ristau J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. .; Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany. .
Hörner-Rieber J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Buchele C; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Klüter S; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Jäkel C; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Baumann L; Institute of Medical Biometry, Heidelberg University Hospital, Heidelberg, Germany.
Andratschke N; Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Garcia Schüler H; Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Guckenberger M; Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Li M; Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Niyazi M; Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Belka C; Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Herfarth K; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), Core Center, Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), Core Center, Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2022 Apr 15; Vol. 17 (1), pp. 75. Date of Electronic Publication: 2022 Apr 15.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:: Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/radiotherapy
Radiosurgery*/methods
Humans ; Magnetic Resonance Imaging/methods ; Male ; Prospective Studies ; Radiation Dose Hypofractionation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies.
Autorzy:: Dendl K; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Finck R; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Giesel FL; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Department of Nuclear Medicine, Düsseldorf University Hospital, Düsseldorf, Germany.
Kratochwil C; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Lindner T; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Mier W; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Cardinale J; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Kesch C; Department of Urology, German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Röhrich M; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Rathke H; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Gampp H; Department of Cardiology, University of Heidelberg, Heidelberg, Germany.
Ristau J; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Adeberg S; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Jäger D; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Debus J; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
Koerber SA; National Center for Tumor Diseases (NCT), Heidelberg, Germany. .; Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany. .; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. .; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2022 Jan; Vol. 49 (2), pp. 721-731. Date of Electronic Publication: 2021 Aug 03.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*
Positron Emission Tomography Computed Tomography*/methods
Biological Transport ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Head-to-head intra-individual comparison of biodistribution and tumor uptake of F-FDG PET/CT in cancer patients.
Autorzy:: Giesel FL; Department of Nuclear Medicine, University Hospital Duesseldorf, Duesseldorf, Germany. .; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany. .
Kratochwil C; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Schlittenhardt J; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Dendl K; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Eiber M; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Staudinger F; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Kessler L; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
Fendler WP; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
Lindner T; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Koerber SA; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Cardinale J; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Sennung D; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, CA, USA.
Roehrich M; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Debus J; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany.
Sathekge M; Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Haberkorn U; Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
Calais J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, CA, USA.
Serfling S; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Buck AL; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, 97080, Wuerzburg, Germany.; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Dec; Vol. 48 (13), pp. 4377-4385. Date of Electronic Publication: 2021 Jun 17.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Neoplasms*/diagnostic imaging
Positron Emission Tomography Computed Tomography*
Female ; Fluorodeoxyglucose F18 ; Gallium Radioisotopes ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Tissue Distribution

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Ga-FAPI-PET/CT in patients with various gynecological malignancies.
Autorzy:: Dendl K; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Finck R; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Mokoala KMG; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Private Bag X169, Pretoria, 0001, South Africa.
Staudinger F; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Schillings L; Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Heger U; Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Röhrich M; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Kratochwil C; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Sathekge M; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Private Bag X169, Pretoria, 0001, South Africa.
Jäger D; Department of Medical Oncology, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site, Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
Giesel FL; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany. .; German Cancer Consortium (DKTK), partner site, Heidelberg, Germany. .; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. .; Department of Nuclear Medicine, University Hospital Duesseldorf, Duesseldorf, Germany. .; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Nov; Vol. 48 (12), pp. 4089-4100. Date of Electronic Publication: 2021 May 29.
Typ publikacji:: Journal Article
MeSH Terms:: Genital Neoplasms, Female*/diagnostic imaging
Positron Emission Tomography Computed Tomography*
Adult ; Female ; Gallium Radioisotopes ; Humans ; Middle Aged ; Retrospective Studies ; Tissue Distribution

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT.
Autorzy:: Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; National Center for Tumor Diseases (NCT), Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.
Finck R; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Dendl K; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Uhl M; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Klinikum Ludwigshafen, Ludwigshafen, Germany.
Lindner T; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Kratochwil C; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Röhrich M; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Rathke H; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Ungerechts G; Department of Medical Oncology, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Adeberg S; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Herfarth K; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Jaeger D; Department of Medical Oncology, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
Giesel FL; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, Germany.; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Nov; Vol. 48 (12), pp. 3918-3924. Date of Electronic Publication: 2021 May 21.
Typ publikacji:: Journal Article
MeSH Terms:: Positron Emission Tomography Computed Tomography*
Sarcoma*/diagnostic imaging
Humans ; Ligands ; Neoplasm Recurrence, Local ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?
Autorzy:: Dendl K; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Department of Nuclear Medicine, Düsseldorf University Hospital, 40225 Düsseldorf, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Kratochwil C; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Cardinale J; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Department of Nuclear Medicine, Düsseldorf University Hospital, 40225 Düsseldorf, Germany.
Finck R; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Dabir M; Department of Nuclear Medicine, Düsseldorf University Hospital, 40225 Düsseldorf, Germany.
Novruzov E; Department of Nuclear Medicine, Düsseldorf University Hospital, 40225 Düsseldorf, Germany.
Watabe T; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Kramer V; Positronpharma SA, Santiago 7500921, Chile.; Center of Nuclear Medicine, PositronMed, Santiago 7501068, Chile.
Choyke PL; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1088, USA.
Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Translational Lung Research Center Heidelberg, German Center for Lung Research DZL, 69120 Heidelberg, Germany.
Giesel FL; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Department of Nuclear Medicine, Düsseldorf University Hospital, 40225 Düsseldorf, Germany.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2021 Sep 30; Vol. 13 (19). Date of Electronic Publication: 2021 Sep 30.
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT.
Autorzy:: Dendl K; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Adeberg S; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Röhrich M; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Kratochwil C; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Haberkorn U; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Giesel FL; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. .; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Jun; Vol. 48 (6), pp. 2059-2061. Date of Electronic Publication: 2021 Feb 04.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Positron Emission Tomography Computed Tomography*
Quinolines*
Female ; Gelatinases ; Humans ; Postpartum Period ; Serine Endopeptidases

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma.
Autorzy:: Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Boesch J; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Kratochwil C; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Schlampp I; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Ristau J; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Winter E; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Zschaebitz S; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Hofer L; Department of Urology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Herfarth K; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Kopka K; German Cancer Consortium (DKTK), Partner Site Dresden, 01328 Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.; Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, 01069 Dresden, Germany.
Holland-Letz T; Department of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Jaeger D; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Hohenfellner M; Department of Urology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner Site Heidelberg, 69120 Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner Site Heidelberg, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Giesel FL; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner Site Heidelberg, 69120 Heidelberg, Germany.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2021 Mar 25; Vol. 13 (7). Date of Electronic Publication: 2021 Mar 25.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer.
Autorzy:: Liermann J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
Syed M; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
Ben-Josef E; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Schubert K; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Schlampp I; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Sprengel SD; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Ristau J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Weykamp F; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Röhrich M; Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner Site Heidelberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Herfarth K; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner Site Heidelberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Giesel FL; Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Naumann P; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2021 Feb 14; Vol. 13 (4). Date of Electronic Publication: 2021 Feb 14.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity.
Autorzy:: Ristau J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Thiel M; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Katayama S; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Radiation Oncology Unit Speyer, Speyer, Germany.
Schlampp I; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Lang K; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Häfner MF; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Radiation Oncology Unit Speyer, Speyer, Germany.
Herfarth K; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg University Hospital, Heidelberg, Germany.; Core Center Heidelberg, German Cancer Consortium (DKTK), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg University Hospital, Heidelberg, Germany.; Core Center Heidelberg, German Cancer Consortium (DKTK), Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany. stefan.koerber@med.uni-heidelberg.de.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2021 Feb 01; Vol. 16 (1), pp. 23. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji:: Clinical Trial; Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Chemoradiotherapy/*mortality
Esophageal Neoplasms/*therapy
Esophageal Squamous Cell Carcinoma/*therapy
Neoplasm Recurrence, Local/*therapy
Radiotherapy, Intensity-Modulated/*mortality
Adult ; Aged ; Aged, 80 and over ; Esophageal Neoplasms/pathology ; Esophageal Squamous Cell Carcinoma/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Retrospective Studies ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers.
Autorzy:: Syed M; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. .; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. .; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. .
Flechsig P; Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Liermann J; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Windisch P; Department for Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Staudinger F; Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Akbaba S; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Koerber SA; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Freudlsperger C; Department of Oral and Maxillofacial Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Plinkert PK; Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Debus J; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Giesel F; Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, DKFZ, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
Adeberg S; Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Nov; Vol. 47 (12), pp. 2836-2845. Date of Electronic Publication: 2020 May 23.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Head and Neck Neoplasms*/diagnostic imaging
Head and Neck Neoplasms*/radiotherapy
Positron Emission Tomography Computed Tomography*
Fibroblasts ; Humans ; Positron-Emission Tomography ; Radiopharmaceuticals ; Radiotherapy Planning, Computer-Assisted ; Tissue Distribution

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer.
Autorzy:: Krug D; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. .; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany. .; Department of Radiation Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, 24105, Kiel, Germany. .
Köder C; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Häfner MF; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Arians N; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Harrabi SB; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Forster T; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Schlampp I; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Sohn C; Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany.
Heil J; Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany.
Hof H; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.; Strahlentherapie Rhein-Pfalz, Neustadt, Germany.
Hörner-Rieber J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner site Heidelberg, Heidelberg, Germany.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2020 Oct 13; Vol. 15 (1), pp. 235. Date of Electronic Publication: 2020 Oct 13.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:: Breast Neoplasms/*radiotherapy
Radiotherapy, Conformal/*adverse effects
Re-Irradiation/*adverse effects
Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Female ; Humans ; Mastodynia/etiology ; Middle Aged ; Prospective Studies ; Radiodermatitis/etiology ; Radiotherapy, Adjuvant ; Radiotherapy, Intensity-Modulated/adverse effects ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.
Autorzy:: Windisch P; Department of Radiation Oncology, Kantonsspital Winterthur, 8400 Winterthur, Switzerland.
Zwahlen DR; Department of Radiation Oncology, Kantonsspital Winterthur, 8400 Winterthur, Switzerland.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
Giesel FL; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), 69120 Heidelberg, Germany.
Adeberg S; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2020 Sep 15; Vol. 12 (9). Date of Electronic Publication: 2020 Sep 15.
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Fatigue following radiotherapy of low-risk early breast cancer - a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419).
Autorzy:: Forster T; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Jäkel C; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Akbaba S; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Krug D; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Schleswig Holstein, Kiel, Germany.
Krempien R; Department of Radiation Oncology, Helios Hospital Berlin-Buch, Berlin, Germany.
Uhl M; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Häfner MF; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
König L; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Harrabi S; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Bernhardt D; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Behnisch R; Institute of Medical Biometry and Informatics, Heidelberg University, Heidelberg, Germany.
Krisam J; Institute of Medical Biometry and Informatics, Heidelberg University, Heidelberg, Germany.
Hennigs A; Department of Gynecology and Obstetrics, Heidelberg University, 69115, Heidelberg, Germany.
Sohn C; Department of Gynecology and Obstetrics, Heidelberg University, 69115, Heidelberg, Germany.
Heil J; Department of Gynecology and Obstetrics, Heidelberg University, 69115, Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.
Hörner-Rieber J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. .; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), Heidelberg, Germany. .; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. .; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2020 Jun 01; Vol. 15 (1), pp. 134. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Breast Neoplasms/*radiotherapy
Fatigue/*etiology
Radiotherapy, Adjuvant/*adverse effects
Radiotherapy, Adjuvant/*methods
Aged ; Breast Neoplasms/surgery ; Fatigue/epidemiology ; Female ; Humans ; Intraoperative Period ; Middle Aged ; Radiation Dose Hypofractionation ; Radiotherapy, High-Energy/methods ; Radiotherapy, Intensity-Modulated/methods ; Research Design

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
Autorzy:: König L; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. .; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. .; National Center for Tumor diseases (NCT), Heidelberg, Germany. .
Häfner MF; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Katayama S; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Tonndorf-Martini E; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bernhardt D; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
von Nettelbladt B; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Weykamp F; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Hoegen P; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Klüter S; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Susko MS; Department of Radiation Oncology, University of California - San Francisco, San Francisco, USA.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.
Hörner-Rieber J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2020 Feb 04; Vol. 15 (1), pp. 30. Date of Electronic Publication: 2020 Feb 04.
Typ publikacji:: Clinical Trial; Journal Article
MeSH Terms:: Adrenal Gland Neoplasms/*secondary
Neoplasms/*pathology
Radiosurgery/*mortality
Radiotherapy Planning, Computer-Assisted/*methods
Adrenal Gland Neoplasms/surgery ; Aged ; Aged, 80 and over ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/surgery ; Prognosis ; Radiotherapy Dosage ; Radiotherapy, Intensity-Modulated/methods ; Retrospective Studies ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) - a prospective, randomized, 2-armed phase-II-trial.
Autorzy:: Arians N; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany. .; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. .; National Center for Tumor diseases (NCT), Heidelberg, Germany. .
Häfner M; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Krisam J; Institute of Medical Biometry and Informatics, Heidelberg University, Heidelberg, Germany.
Lang K; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Wark A; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Hommertgen A; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2020 Jan 21; Vol. 20 (1), pp. 52. Date of Electronic Publication: 2020 Jan 21.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:: Anus Neoplasms/*therapy
Chemoradiotherapy/*adverse effects
Pelvic Neoplasms/*therapy
Radiation Injuries/*pathology
Radiotherapy, Intensity-Modulated/*adverse effects
Vaginal Diseases/*pathology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anus Neoplasms/pathology ; Female ; Humans ; Middle Aged ; Pelvic Neoplasms/pathology ; Prognosis ; Prospective Studies ; Quality of Life ; Radiation Injuries/etiology ; Radiotherapy Dosage ; Vaginal Diseases/etiology ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial.
Autorzy:: Koerber SA; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. Stefan.Koerber@med.uni-heidelberg.de.; National Center for Tumor diseases (NCT), Heidelberg, Germany. Stefan.Koerber@med.uni-heidelberg.de.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. Stefan.Koerber@med.uni-heidelberg.de.
Katayama S; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Sander A; Institute of Medical Biometry and Informatics, Heidelberg University, Heidelberg, Germany.
Jaekel C; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Haefner MF; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner site Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Herfarth K; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2019 Jul 10; Vol. 14 (1), pp. 122. Date of Electronic Publication: 2019 Jul 10.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Quality of Life*
Prostatic Neoplasms/*radiotherapy
Proton Therapy/*methods
Radiotherapy Planning, Computer-Assisted/*methods
Humans ; Male ; Prognosis ; Prospective Studies ; Radiation Dose Hypofractionation ; Radiotherapy Dosage

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
Autorzy:: Zschaeck S; Department of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany. .; Charité Universitätsmedizin Berlin, Klinik für Radioonkologie und Strahlentherapie, Augustenburger Platz 1, 13353, Berlin, Germany. .
Lohaus F; Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Dresden, Germany.
Beck M; Department of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Habl G; Department of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.; Institute of Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München (HMGU), München, Germany.
Kroeze S; Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Zamboglou C; Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Dresden, Germany.
Koerber SA; Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; German cancer research center (DKFZ) and german consortium for translational cancer research (DKTK), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; German cancer research center (DKFZ) and german consortium for translational cancer research (DKTK), Heidelberg, Germany.
Hölscher T; Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Dresden, Germany.
Wust P; Department of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Ganswindt U; Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Innsbruck, Austria.
Baur ADJ; Department of of Radiology, Universitätsmedizin Berlin, Berlin, Germany.
Zöphel K; Nuclear Medicine Department, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Cihoric N; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, München, Switzerland.
Guckenberger M; Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Combs SE; Department of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.; Institute of Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München (HMGU), München, Germany.; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Munich, Munich, Germany.
Grosu AL; Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Dresden, Germany.
Ghadjar P; Department of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Belka C; Department of Radiation Oncology, Ludwig-Maximilians-University, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) partner site Munich, Munich, Germany.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2018 May 11; Vol. 13 (1), pp. 90. Date of Electronic Publication: 2018 May 11.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Antigens, Surface/*metabolism
Glutamate Carboxypeptidase II/*metabolism
Positron-Emission Tomography/*methods
Practice Patterns, Physicians'/*trends
Prostatic Neoplasms/*radiotherapy
Radiopharmaceuticals/*therapeutic use
Humans ; Male ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/metabolism ; Surveys and Questionnaires

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Koerber SA"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język